BR112012004046A2 - bifidobacterium longum e distúrbios gi funcionais. - Google Patents

bifidobacterium longum e distúrbios gi funcionais.

Info

Publication number
BR112012004046A2
BR112012004046A2 BR112012004046A BR112012004046A BR112012004046A2 BR 112012004046 A2 BR112012004046 A2 BR 112012004046A2 BR 112012004046 A BR112012004046 A BR 112012004046A BR 112012004046 A BR112012004046 A BR 112012004046A BR 112012004046 A2 BR112012004046 A2 BR 112012004046A2
Authority
BR
Brazil
Prior art keywords
bifidobacterium longum
disorders
functional
present
treat
Prior art date
Application number
BR112012004046A
Other languages
English (en)
Other versions
BR112012004046B1 (pt
Inventor
Verdu De Bercik Elena
Bergonzelli De Gonda Gabriela
Mclean Peter
Bercik Premysl
Michael Collins Stephen
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41508246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012004046(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112012004046A2 publication Critical patent/BR112012004046A2/pt
Publication of BR112012004046B1 publication Critical patent/BR112012004046B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se, de modo geral, ao campo das bactérias probióticas. em particular, ela se refere ao bifidobacterium longum, tal como bifidobacterium longum atcc baa-999 e seu uso em composições ingeríveis. a composição descrita na presente invenção pode ser usada para tratar ou prevenir distúrbios gi funcionais.
BR112012004046-4A 2009-08-25 2010-08-24 composição compreendendo bifidobacterium longum atcc baa-999 para tratamento e/ou prevenção de distúrbios gastrointestinais funcionais ligados à ansiedade BR112012004046B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09168590.9A EP2289527B1 (en) 2009-08-25 2009-08-25 Bifidobacterium longum and functional GI disorders
EP09168590.9 2009-08-25
PCT/EP2010/062320 WO2011023689A1 (en) 2009-08-25 2010-08-24 Bifidobacterium longum and functional gi disorders

Publications (2)

Publication Number Publication Date
BR112012004046A2 true BR112012004046A2 (pt) 2017-05-30
BR112012004046B1 BR112012004046B1 (pt) 2021-02-17

Family

ID=41508246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004046-4A BR112012004046B1 (pt) 2009-08-25 2010-08-24 composição compreendendo bifidobacterium longum atcc baa-999 para tratamento e/ou prevenção de distúrbios gastrointestinais funcionais ligados à ansiedade

Country Status (17)

Country Link
US (3) US10028981B2 (pt)
EP (2) EP2289527B1 (pt)
JP (4) JP2013503130A (pt)
CN (2) CN102573863A (pt)
AU (1) AU2010288546B2 (pt)
BR (1) BR112012004046B1 (pt)
CA (1) CA2772163C (pt)
CL (1) CL2012000487A1 (pt)
DK (1) DK2289527T3 (pt)
ES (1) ES2664828T3 (pt)
IN (1) IN2012DN01638A (pt)
MX (1) MX2012002402A (pt)
RU (1) RU2012111253A (pt)
SG (1) SG178499A1 (pt)
TR (1) TR201807143T4 (pt)
WO (1) WO2011023689A1 (pt)
ZA (1) ZA201202155B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
ES2664828T3 (es) 2009-08-25 2018-04-23 Nestec S.A. Bifidobacterium longum y trastornos GI funcionales
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
IN2014DN07752A (pt) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
WO2016070151A1 (en) 2014-10-31 2016-05-06 Whole Biome. Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
WO2016198528A1 (en) 2015-06-11 2016-12-15 Nestec S.A. Dietary supplement
EP3344269A1 (en) * 2015-08-31 2018-07-11 Nestec S.A. Methods and compositions using bifidobacterium longum to optimize breastfeeding
MX2018001851A (es) * 2015-08-31 2018-05-17 Nestec Sa Metodos y composiciones que usan bifidobacterium longum para tratar o prevenir sintomas depresivos.
BR112018000786B1 (pt) * 2015-08-31 2022-06-14 Société des Produits Nestlé S.A. Uso de b. longum atcc baa-999 na preparação de composição comestível para tratar depressão
US10835545B2 (en) 2015-10-28 2020-11-17 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
WO2017071716A1 (en) 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
JP6353478B2 (ja) * 2016-03-28 2018-07-04 日清食品ホールディングス株式会社 セロトニン分泌促進能力を有するビフィズス菌
CN107050062A (zh) * 2016-11-08 2017-08-18 江西益盟科技有限公司 治疗便秘的乳酸菌组合物及其制备方法
CN106579414A (zh) * 2016-12-26 2017-04-26 北京康比特体育科技股份有限公司 一种缓解运动性腹泻的组合物
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
US11529381B2 (en) 2017-02-28 2022-12-20 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
AU2018263770A1 (en) * 2017-05-05 2019-10-03 Societe Des Produits Nestle S.A. Treatment of infant colic
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
JP7285096B2 (ja) 2018-03-28 2023-06-01 森永乳業株式会社 ストレス緩和用組成物並びに該ストレス緩和用組成物を用いた医薬品組成物及び飲食品組成物
AU2020299976A1 (en) * 2019-07-01 2021-12-16 Société des Produits Nestlé S.A. Serpin production
JP2021014421A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 Ｑｏｌ改善剤
JP2021014422A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 便性改善剤
CN111187734A (zh) * 2019-12-25 2020-05-22 生合生物科技（扬州）有限公司 长双歧杆菌bl986、由其制备的冻干粉及冻干粉的应用
US20230218695A1 (en) * 2020-05-20 2023-07-13 Societe Des Produits Nestle S.A. Improvement of insoluble fibre fermentability and short chain fatty acid production by bifidobacterium longum

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
DE10008279A1 (de) * 2000-02-23 2001-08-30 Meggle Gmbh Milchzucker enthaltende Zusammensetzung
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
US7033629B2 (en) * 2001-08-31 2006-04-25 Nutricopia Inc. Nutritional frozen dessert and methods of manufacture
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
JP2004262773A (ja) * 2003-02-17 2004-09-24 Ryoshoku Kenkyukai 免疫機能改善を目的としたビフィズス菌製剤
US20040265279A1 (en) 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
PT1638414E (pt) * 2003-06-23 2009-07-13 Nestec Sa Fórmula para lactentes ou fórmula de transição
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
US8134942B2 (en) * 2005-08-24 2012-03-13 Avaak, Inc. Communication protocol for low-power network applications and a network of sensors using the same
ZA200803998B (en) * 2005-11-14 2009-08-26 Unilever Plc Edible product containing ginseng polysaccharides and beneficial bacteria
JP2007169200A (ja) * 2005-12-21 2007-07-05 Morinaga Milk Ind Co Ltd インフルエンザ感染予防のための医薬及び飲食品
PT1986669E (pt) * 2006-02-15 2012-05-15 Nestec Sa Utilização de bifidobacterium longum para a prevenção e tratamento de inflamação
CA2644968A1 (en) 2006-03-07 2007-09-13 Nestec S.A. Synbiotic mixture
EP1961308A1 (en) * 2007-02-21 2008-08-27 Nestec S.A. Nutritionally balanced frozen dessert
EP1974735A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Reduction of risk of diarrhoea
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
EP2227239A2 (en) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
BRPI0820802A2 (pt) * 2007-12-17 2015-06-16 Univ Florida Materiais e métodos para tratamento de proliferação vascular ocular patológica
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
ES2664828T3 (es) 2009-08-25 2018-04-23 Nestec S.A. Bifidobacterium longum y trastornos GI funcionales
CN112074193A (zh) * 2018-01-29 2020-12-11 精密生物集团有限公司 一种用于预防和治疗肠易激综合征的组合产品

Also Published As

Publication number Publication date
SG178499A1 (en) 2012-04-27
JP2013503130A (ja) 2013-01-31
ZA201202155B (en) 2014-09-25
AU2010288546A1 (en) 2012-03-22
CL2012000487A1 (es) 2012-08-31
EP2289527B1 (en) 2018-02-21
CA2772163C (en) 2017-11-07
RU2012111253A (ru) 2013-10-10
ES2664828T3 (es) 2018-04-23
US20190134104A1 (en) 2019-05-09
US20220280576A1 (en) 2022-09-08
WO2011023689A1 (en) 2011-03-03
EP2470188A1 (en) 2012-07-04
US20120230956A1 (en) 2012-09-13
TR201807143T4 (tr) 2018-06-21
EP2289527A1 (en) 2011-03-02
CN106072658A (zh) 2016-11-09
CN102573863A (zh) 2012-07-11
US11452745B2 (en) 2022-09-27
IN2012DN01638A (pt) 2015-06-05
MX2012002402A (es) 2012-04-02
JP2016074682A (ja) 2016-05-12
JP7096652B2 (ja) 2022-07-06
US10028981B2 (en) 2018-07-24
JP2020183385A (ja) 2020-11-12
JP7096652B6 (ja) 2022-08-01
BR112012004046B1 (pt) 2021-02-17
US11957720B2 (en) 2024-04-16
DK2289527T3 (en) 2018-04-23
CA2772163A1 (en) 2011-03-03
AU2010288546B2 (en) 2015-08-20
JP2018048112A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
BR112012004046A2 (pt) bifidobacterium longum e distúrbios gi funcionais.
SG10201901259RA (en) Prebiotic formulations and methods of use
GB2511993A (en) Prebiotic formulations and methods of use
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
CL2011002818A1 (es) Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios.
WO2012112777A3 (en) Biosynthesis of human milk oligosaccharides in engineered bacteria
MY195771A (en) Fucosyllactose as Breast Milk Identical Non-Digestible Oligosaccharide With New Functional Benefit
BR112012017978A2 (pt) fórmulas nutricionais contendo simbióticos
MX354047B (es) Cepas/celulas de lactobacillus secadas por aspersion, y el uso de las mismas contra helicobacter pylori.
BR112013000921A2 (pt) tratamento de infecções pulmonares pela administração de tobramicina por aerolização
BR112015027536A2 (pt) composição compreendendo mistura de bactérias ácidas lácticas, bem como uso da referida mistura
MX337041B (es) Cepas y metodos para mejorar la salud y/o desempeño de los rumiantes.
WO2010008491A3 (en) Lactose compositions with decreased lactose content
EP2316412A3 (en) High-clarity aqueous concentrates of 4-hexylresorcinol
MY158310A (en) Prevention and treatment of allergic diarrhoea
MX342947B (es) Tratamiento de diabetes tipo 2.
IN2012DN01414A (pt)
MX360411B (es) Uso de tiosulfato para potenciar el efecto anti-patogenico de los lactobacilos.
EA201291440A1 (ru) Пробиотические штаммы для применения при повышении трансэпителиального сопротивления
BR112015004813A8 (pt) composição de sabão, método de desinfecção de uma superfície e utilizações de uma composição
GEP201606589B (en) Novel bacterium and extracts of said bacterium and the use of same in dermatology
EA201270547A1 (ru) Фармацевтическая композиция

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Ipc: A61K 35/74 (2015.01), A23K 10/18 (2016.01), A23L 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/02/2021, OBSERVADAS AS CONDICOES LEGAIS.